W
WAVEMAN · COMPANY
ULS · Ul Solutions Inc.
> Ask across nine datasets ⌘K
LIVE
TEAM-2.62% 13F +440META+1.00% 13F +2,694RCG+0.35% CLUSTERUTHR-0.54% 13F +425CRWV+5.68% 13F +694CRM-1.97% 13F +1,019CVNA+1.58% 13F +795TPL-1.11% 13F +444NET-1.96% 13F +711MSTR-1.39% 13F +527DELL+1.50% 13F +1,204CRWD-0.87% 13F +1,383ANET+1.22% 13F +1,324COIN-4.18% 13F +475TEAM-2.62% 13F +440META+1.00% 13F +2,694RCG+0.35% CLUSTERUTHR-0.54% 13F +425CRWV+5.68% 13F +694CRM-1.97% 13F +1,019CVNA+1.58% 13F +795TPL-1.11% 13F +444NET-1.96% 13F +711MSTR-1.39% 13F +527DELL+1.50% 13F +1,204CRWD-0.87% 13F +1,383ANET+1.22% 13F +1,324COIN-4.18% 13F +475
← ALL COMPANIES

ULS

UL Solutions Inc.
PHARMA & BIOTECH · SERVICES-TESTING LABORATORIES · CIK 0001901440
FORM 144 · 1☆ WATCH
INSIDER NET · 180D
-$11.1M
open-market buys minus sells, Form 4 codes P and S
INSIDER BUYERS · 180D
0
CONGRESS BUYERS · 1Y
0
FUNDS ADDED · QTR
234
13F, latest reported quarter
REVENUE GROWTH
+6.4%
XBRL, annual
NET MARGIN
10.6%
CONVERSIONS · 180D
25
codes C/M, not in net · $633.1K priced
SEVEN FACTS, RANKED AGAINST THE SECTOR · RANK IS NOT A FORECAST
INSIDERS
net -$11.1M over 180 days
-$3.4M over 90 days
below 85% of Pharma & Biotech
CONGRESS
no member of Congress has reported trading it
FUNDS
234 funds added or opened last quarter
more than 90% of Pharma & Biotech
REVENUE
+6.4% year over year
more than 56% of Pharma & Biotech
MARGIN
10.6% net margin
more than 81% of Pharma & Biotech
BUYBACKS
no share repurchases reported
SHORT
no short interest reported
THE SITUATION · EVERY LINE IS ONE RULE OVER ONE DATASET
Insiders are net sellers: -$11.1M across 5 people in 180 days.
234 funds added or opened positions in the latest 13F quarter, of 393 holders.
The year, with the filings on it
Total return indexed to 100 over the last 12 months · every marker is a federal filing, placed at its date — hover any marker for the detail
TOTAL 12M RETURN +15.9%
+15.9%12M
-2%+20%+42%+64%2025-092025-102025-122026-032026-052026-072026-09 2025-12-05 · ULSE Inc. sold $975.0M2025-12-19 · ULSE Inc. sold $146.2M2026-06-02 · Schjotz Gitte sold $1.2M2026-06-03 · Schjotz Gitte sold $956.7K2026-05-01 · Scanlon Jennifer F. sold $871.5K2026-05-07 · Schjotz Gitte sold $831.7K2026-09-01 · Scanlon Jennifer F. sold $771.6K2026-06-01 · Scanlon Jennifer F. sold $747.5K2026-04-01 · Scanlon Jennifer F. sold $650.4K2026-05-11 · Uggetti Alberto sold $610.0K2026-08-03 · Scanlon Jennifer F. sold $519.2K2026-06-01 · Scanlon Jennifer F. sold $502.4K2026-07-01 · Scanlon Jennifer F. sold $470.0K2026-04-01 · Scanlon Jennifer F. sold $418.4K2026-05-21 · Hecker Friedrich sold $408.2K2026-07-01 · Scanlon Jennifer F. sold $356.6K2026-08-03 · Scanlon Jennifer F. sold $330.3K2026-08-03 · Scanlon Jennifer F. sold $301.5K2026-05-01 · Scanlon Jennifer F. sold $273.1K2026-07-01 · Scanlon Jennifer F. sold $262.7K2026-05-28 · Uggetti Alberto sold $234.2K2026-09-01 · Scanlon Jennifer F. sold $149.2K2026-07-01 · Scanlon Jennifer F. sold $120.4K2026-06-09 · PEPPING KAREN K sold $70.9K2026-07-01 · Scanlon Jennifer F. sold $30.5K2025-09-08 · Genovesi John A bought $2.4K2025-12-08 · Genovesi John A bought $2.3K2025-12-08 · Hancock Lynn H bought $6232026-07-01 · JENNIFER SCANLON filed to sell $3.8M
INSIDER BUYINSIDER SELLFORM 144
INDEXED RETURN, DIVIDEND-ADJUSTED — NOT A PRICE CHART · LARGE TRADES DRAWN FIRST WHEN A NAME FILES HEAVILY
Live price
Daily candles from TradingView, on their licence — no filings are marked on this one
WHY THIS NAME IS ON THE DESK
Insiders have filed to sell — before selling.
The record shows a net $11.1M sold by insiders over 180 days, 234 funds added last quarter, $3.8M in planned Form 144 sales. Every figure is a federal filing, dated the day it became public.
Same sector, ranked by filing activity
Sector from the SEC's own SIC classification
Insider transactions
Form 4 purchases and sales (codes P and S) — grants, option exercises and preferred conversions excluded

Over the last 180 days, UL Solutions Inc. insiders sold a net $11.1M of stock across 63 Form 4 purchases and sales, with 0 insider(s) buying. Source: SEC Form 4 filings, as of 2026-09-06.

INSIDER
FILED
SHARES
VALUE
Scanlon Jennifer F.
President and CEO
SELL
2026-09-01
10,495.0
$771.6K
Scanlon Jennifer F.
President and CEO
SELL
2026-09-01
2,005.0
$149.2K
Scanlon Jennifer F.
President and CEO
SELL
2026-08-03
3,629.0
$330.3K
Scanlon Jennifer F.
President and CEO
SELL
2026-08-03
3,281.0
$301.5K
Scanlon Jennifer F.
President and CEO
SELL
2026-08-03
5,590.0
$519.2K
63 TRANSACTIONS ON RECORD

Showing the most recent few. Create a free account to see 58 more transactions on record, the cross-source screener and CSV export. We store only your email address, and there is no password to create.

Institutional holders
13F · holdings as of the latest quarter funds have reported
BlackRock, Inc.
7,131,683.0 sh
$726.4M
Capital International Investors
6,115,196.0 sh
$622.9M
KAYNE ANDERSON RUDNICK INVESTMENT MANAGEMENT LLC
4,694,443.0 sh
$478.2M
VANGUARD CAPITAL MANAGEMENT LLC
3,504,948.0 sh
$357.0M
Capital Research Global Investors
3,367,530.0 sh
$343.0M
SCHEDULE 13D/G
No 5%+ ownership filings
Nobody has crossed 5% with a filing obligation. Absence is a fact here, not missing data.
Planned sales · Form 144
Filed before the sale — intent, not a trade
JENNIFER SCANLON
FILED 2026-07-01
$3.8M
Fund concentration
N-PORT · funds ranked by how much of THEMSELVES they put in this stock — the conviction number 13F cannot show
Wasatch Global Select Fund
$526.9K POSITION · AS OF 2026-03-31
4.6%
Virtus KAR Small-Mid Cap Core Fund
$63.4M POSITION · AS OF 2026-03-31
4.4%
Wasatch Long/Short Alpha Fund
$1.6M POSITION · AS OF 2026-03-31
4.4%
Wasatch U.S. Select Fund
$676.0K POSITION · AS OF 2026-03-31
4.2%
REYNDERS, MCVEIGH CORE EQUITY FUND
$4.1M POSITION · AS OF 2026-04-30
4.0%
Transamerica Small Cap Growth
$2.6M POSITION · AS OF 2026-04-30
3.3%
SEC N-PORT, MONTHLY WITH A ~60-DAY PUBLIC LAG · FUNDS ≥ $10M · % = SHARE OF THE FUND'S OWN BOOK
Executive pay vs shareholder return · Ms. Scanlon
DEF 14A pay-versus-performance disclosure · both the headline pay and the SEC's mark-to-market figure, beside the return the company delivered and the return of the peer group it chose itself
FY
CEO TOTAL
ACTUALLY PAID
OTHER NEOs AVG
TSR
PEER TSR
2025
$15.3M
$56.5M
$3.3M
+129%
+26%
2024
$18.1M
$43.1M
$3.7M
+44%
+8%
TAGGED BY THE COMPANY UNDER SEC ITEM 402(v) · RETURN IS CUMULATIVE FROM THE START OF THE DISCLOSURE PERIOD · GREEN WHERE THE COMPANY BEAT ITS OWN PEER GROUP
Fundamentals
Annual figures from XBRL filings · pick a past date to see them exactly as the market knew them then — restatements and all
2025-122024-122023-122022-12
REVENUE$3.1B$2.9B$2.7B$2.5B
OPERATING INCOME$522.0M$462.0M$368.0M$412.0M
NET INCOME$325.0M$326.0M$260.0M$293.0M
EPS (DILUTED)1.601.621.301.47
OPERATING CASH FLOW$600.0M$524.0M$467.0M$372.0M
CASH$295.0M$298.0M$315.0M
LONG-TERM DEBT$491.0M$692.0M$904.0M
DIVIDENDS PAID$104.0M$100.0M$680.0M$1.6B
SEC XBRL · FISCAL-YEAR PERIODS · AS KNOWN ON 2026-09-06 · NOBODY ELSE SHOWS FUNDAMENTALS AS OF A PAST DATE
W WAVEMAN

Public filings, honestly analyzed. Official US government sources in one desk — every figure carries the date it was filed, and the methodology is published, backtest included.

SEC FORM 4FORM 13F 13D/GFORM 144XBRL STOCK ACTCONTRACTSFEC CFPBNRC
© 2026 WAVEMAN · SOURCE: SEC EDGAR & OFFICIAL GOVERNMENT DATA · NOT INVESTMENT ADVICE · CHART BY TRADINGVIEW · UPDATED 2026-09-06 ALL SYSTEMS LIVE FOR MACHINES →